Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bio-Path Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $0.44 Mil. Bio-Path Holdings's Total Assets for the quarter that ended in Dec. 2023 was $3.22 Mil.
The historical rank and industry rank for Bio-Path Holdings's Equity-to-Asset or its related term are showing as below:
BPTH'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.14 Med: 0.91 Max: 0.96
Current: 0.14
During the past 13 years, the highest Equity to Asset Ratio of Bio-Path Holdings was 0.96. The lowest was 0.14. And the median was 0.91.
BPTH's Equity-to-Asset is ranked worse than 80.95% of 1564
companies
in the Biotechnology industry
Industry Median: 0.66
vs BPTH: 0.14
Bio-Path Holdings Equity-to-Asset Historical Data
The historical data trend for Bio-Path Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Path Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Path Holdings Equity-to-Asset Distribution
For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Bio-Path Holdings's Equity-to-Asset falls into.
Bio-Path Holdings Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Bio-Path Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Bio-Path Holdings Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Bio-Path Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Bio-Path Holdings (Bio-Path Holdings) Business Description
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BPTH has been successfully added to your 